Mallinckrodt Announces Board of Directors and Leadership Updates
Four Directors Added to Board Bring Seasoned Experience in Pharmaceuticals, Healthcare, Finance and Operations
Paul Bisaro Returns as Board Chair
Siggi Olafsson Will Continue as President, CEO and Board Member
Select professional highlights of Mallinckrodt's new directors include:
Paul Bisarois a healthcare industry leader with more than three decades of leadership experience at generic and branded pharmaceutical companies. He served as Mallinckrodt's Board Chair from June 2022to November 2023. Mr. Bisaropreviously served as President, CEO and a director of Impax Laboratories, Executive Chairman of Amneal Pharmaceuticals, Executive Chairman of Allergan, President and CEO of Actavis (formerly Watson Pharmaceuticals), and President, Chief Operating Officer and a director of Barr Pharmaceuticals. Mr. Bisaroserves on the boards of Zoetis and Myriad Genetics and previously served on the boards of TherapeuticsMD and Zimmer Biomet. Katina Dortonhas more than 20 years of finance and healthcare experience across fundraising, mergers and acquisitions, and business development, most recently serving as Chief Financial Officer of NodThera, a private biotechnology company. She previously served as CFO of Repare Therapeutics, AVROBIOand Inmatics and, earlier in her career, was a healthcare investment banker at Morgan Stanley and Needham. Ms. Dortonserves on the boards of Fulcrum Therapeutics and TScan Therapeutics and previously served on the boards of Pandion Therapeutics and US Ecology, among others. Abbas Hussainhas more than 30 years of leadership and operating experience in healthcare, most recently serving as CEO of Vifor. He previously served as GlaxoSmithKline's Global President, Pharmaceuticals & Vaccines, and, earlier in his career, in various leadership roles at Eli Lilly and Company. Mr. Hussainalso has served on the boards of Teva Pharmaceuticals, Aspen Pharmacare, Vifor, ViiV Healthcareand Cochlear, among others. Wes Wheelerhas more than 40 years of diversified leadership experience in healthcare, including business turnarounds and transformations, manufacturing, marketing, engineering, R&D and supply chain. He is currently a Pharmaceutical Services Consultant to KKR. He previously served as President of UPS Healthcareand its subsidiary Marken LLP, CEO, President and a director of Patheon (now a Thermo Fisher Scientific company), and President, R&D and Global Manufacturing at Valeant Pharmaceuticals. Earlier in his career, he held various leadership roles at GlaxoSmithKline and ExxonMobil in engineering, marketing and manufacturing.
With the appointment of Messrs Bisaro, Hussain and Wheeler and
Mallinckrodt is a global business consisting of multiple wholly owned subsidiaries that develop, manufacture, market and distribute specialty pharmaceutical products and therapies. The Company's Specialty Brands reportable segments' areas of focus include autoimmune and rare diseases in specialty areas like neurology, rheumatology, hepatology, nephrology, pulmonology, ophthalmology, and oncology; immunotherapy and neonatal respiratory critical care therapies; analgesics; and gastrointestinal products. Its Specialty Generics reportable segment includes specialty generic drugs and active pharmaceutical ingredients. To learn more about Mallinckrodt, visit www.mallinckrodt.com.
Senior Vice President, Finance and CFO, Specialty Generics
Vice President, Investor Relations
Mallinckrodt, the "M" brand mark and the Mallinckrodt Pharmaceuticals logo are trademarks of a Mallinckrodt company. Other brands are trademarks of a Mallinckrodt company or their respective owners. ©2024.
View original content to download multimedia:https://www.prnewswire.com/news-releases/mallinckrodt-announces-board-of-directors-and-leadership-updates-302052017.html
SOURCE Mallinckrodt plc